FGP
BEAM icon

Freestone Grove Partners’s Beam Therapeutics BEAM Stock Holding History

Freestone Grove Partners’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-11,115
Closed -$189K – 711
2025
Q2 		$189K Buy
+11,115
New +$194K ﹤0.01% 635

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Freestone Grove Partners's BEAM Position: Q3 2025 in Review

Freestone Grove Partners sold out of Beam Therapeutics (BEAM) in Q3 2025, closing a stake of 11,115 shares — an estimated $189K sold.

Freestone Grove Partners first reported a position in BEAM in Q2 2025 and held it in 1 quarter. The position peaked at $189K in Q2 2025. 218 funds tracked by Wall St. Rank hold BEAM as of Q3 2025.

  • Freestone Grove Partners reported no remaining Beam Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Freestone Grove Partners sold 11,115 Beam Therapeutics shares in Q3 2025, an estimated $189K.
  • Freestone Grove Partners first reported a position in Beam Therapeutics in Q2 2025 and held it in 1 quarter.
  • Freestone Grove Partners's Beam Therapeutics position peaked at $189K in Q2 2025.
  • 218 funds tracked by Wall St. Rank held Beam Therapeutics as of Q3 2025.

Based on Freestone Grove Partners's 13F filing for Q3 2025, filed 14 Nov 2025.